
Notice of Annual General Meeting

Tuesday 1 December 2026 at 3:30 pm CET
Holtedam 3 (Aage Louis-Hansen Auditoriet)
Humlebæk, Denmark



Davis
User, Continence Care

Coloplast

To the shareholders of Coloplast A/S

6 November 2026

Notice of Annual General Meeting

The general meeting will be held on **Tuesday, 1 December 2026, at 3:30 pm CET** at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium).

Coffee, tea, and cake will be served at the same location before the general meeting from 3:00 pm CET to 3:30 pm CET.

The general meeting, which is also transmitted via live webcast on the company's website, www.coloplast.com, will be held in Danish. The general meeting will be opened by the Chairman of the Board of Directors and will be presided over by a chairman appointed by the Board of Directors.

Agenda with complete proposals

1. Report by the Board of Directors on the activities of the company during the past financial year.

2. Presentation and approval of the audited annual report.

3. Resolution on the distribution of profit in accordance with the approved annual report.

4. Presentation and approval of the remuneration report.

5. Approval of the Board of Directors' remuneration for the current financial year.

   The Board of Directors proposes that the general meeting approves the following remuneration to the members of the Board of Directors for the financial year 2026/27, which is unchanged compared to the financial year 2025/26:

   - Members of the Board of Directors: DKK 500,000 (base fee).
   - Chairman of the Board of Directors: DKK 1,500,000 (equivalent to 3x base fee).
   - Deputy Chairman of the Board of Directors: DKK 875,000 (equivalent to 1.75x base fee).

   The Board of Directors has established an Audit Committee and a Remuneration and Nomination Committee. For the financial year 2026/27, the Board of Directors proposes the following fees to committee members for the additional duties associated with their committee work, with the fees remaining unchanged from the financial year 2025/26:

   - A fee to each member of the Audit Committee of DKK 300,000 and a fee to the chairman of the Audit Committee of DKK 500,000.
   - A fee to each member of the Remuneration and Nomination Committee of DKK 200,000 and a fee to the chairman of the Remuneration and Nomination Committee of DKK 300,000.

   In addition, the members of the Board of Directors may be reimbursed for certain expenses etc. as described in the company's remuneration policy.

6. Proposals from the Board of Directors or shareholders.

   6.1 Amendment of the articles of association (place of the annual general meeting).

   With effect from 1 January 2027, the Capital Region of Denmark will be combined with Region Zealand to form the new Region of Eastern Denmark. According to the current article 6 of the company's articles

of association, general meetings must be held in the Capital Region of Denmark. For the purpose of preparing the articles of association for the combination, the Board of Directors proposes that the general meeting adopt an amendment to article 6 of the articles of association. The proposal implies that article 6 of the articles of association will have the following wording:

"The general meetings of the Company are held in the Region of Eastern Denmark as directed by the Board of Directors. The annual general meeting shall be held every year before the end of December.

Extraordinary general meetings shall be held as and when requested by the Board of Directors or by the auditor. Moreover, extraordinary general meetings shall be convened within two weeks when requested in writing for the purpose of transacting specific business by shareholders holding at least 5% of the share capital.

Any questions by shareholders to the agenda and other documents for the purpose of the general meeting shall be received by the Company not later than one week before the date of the general meeting."

7. Election of members to the Board of Directors.

   The Board of Directors proposes re-election of all board members. The following board members are thus all running for re-election:

   Jette Nygaard-Andersen
   Niels Peter Louis-Hansen
   Annette Brüls
   Carsten Hellmann
   Marianne Wiinholt
   Niels B. Christiansen

   In addition, the Board of Directors proposes the election of Charl van Zyl as a new member of the Board of Directors. Charl van Zyl is currently President & CEO of H. Lundbeck A/S, a role he has held since 2023. Charl van Zyl is also a member of the Board of Directors of Bavarian Nordic A/S. Charl van Zyl will bring extensive experience and competencies within strategic growth, commercial execution, financial value creation and R&D investments and pipeline advancement from global and highly regulated healthcare businesses to the Board of Directors.

   A more detailed description of the candidates' special competencies and independence as well as management positions in other companies and demanding organisational tasks is provided in Annex 1 to this notice and is also available on the company's website, www.coloplast.com. The information is also available upon request to the company's Investor Relations department by telephone +45 4911 1800.

8. Election of auditors.

   The Board of Directors proposes re-election of EY Godkendt Revisionspartnerselskab ("EY") as recommended by the Audit Committee. The election applies to statutory financial reporting as well as assurance engagements relating to sustainability reporting. The Audit Committee's recommendation has not been influenced by any third party and has not been subject to any agreement with any third party under which the election of certain auditors or audit firms by the shareholders would be restricted.

9. Authorisation to the chairman of the annual general meeting.

   The Board of Directors proposes that the general meeting authorises the chairman of the general meeting, with full right of substitution, to apply for registration of the resolutions passed and to make any such amendments thereto that the Danish Business Authority or other authorities may require or recommend as a condition for registration or approval, as well as to make and apply for registration of linguistic and other non-substantive adjustments to the company's articles of association.

10. Any other business.

    No other proposals have been tabled by the Board of Directors or by shareholders for consideration at the general meeting.

Majority requirement

Adoption of agenda item 6.1 requires that at least half of the share capital is represented at the general meeting, and that the resolution is adopted with at least 2/3 of both the votes cast and of the voting share capital represented at the general meeting, cf. article 12 of the articles of association.

The adoption of the proposed resolutions under agenda items 2, 3, 4, 5, 7, 8 and 9 requires a simple majority of votes pursuant to article 12 of the articles of association.

Shareholder information

The total share capital of the company amounts to DKK 228,200,000, of which DKK 18,000,000 are A-shares divided into shares of DKK 1 each or multiples thereof, and DKK 210,200,000 are B-shares divided into shares of DKK 1 each.

A shareholder's right to attend and vote at the general meeting is determined by the shares held by the shareholder on the record date, which is **Tuesday, 24 November 2026.**

Each A-share of DKK 1 entitles the holder to ten votes, and each B-share of DKK 1 entitles the holder to one vote.

Any shareholder, attending the general meeting, may submit questions to the management at the general meeting. Questions regarding the agenda and other documents for the use of the general meeting may also be submitted in writing and are requested to be received by the company no later than one week prior to the date of the general meeting. Written questions must clearly identify the shareholder and be sent by email to dkadim@coloplast.com and dkammi@coloplast.com or by ordinary mail to Coloplast A/S, Holtedam 1, 3050 Humlebæk, Denmark, marked "Investor Relations".

The following information will be available in the "Investor Relations" section on the company's website, www.coloplast.com, as of Friday, 6 November 2026:

- The notice convening the general meeting, including agenda and complete proposals.
- The total number of shares and voting rights as of the date when the general meeting is convened, including the total number for each share class.
- The annual report for 2025/26.
- The remuneration report for 2025/26.
- Forms to be used for registration, voting by proxy and postal voting.

The notice convening the general meeting, including the complete proposals for consideration at the general meeting has also been sent to any shareholder registered in the shareholders' register, who has so requested. Furthermore, a registration form and a proxy and postal voting form are attached to the notice.

Payment of dividends

Dividends approved at the general meeting will be at the disposal of the shareholders on Friday, 4 December 2026, through the account-holding bank Nordea.

See page 6 of the 2025/26 Annual Report for additional information about dividends.

Admission cards

Admission cards will be issued to anyone who, according to the shareholders' register, is registered as a shareholder on the record date, Tuesday, 24 November 2026, or from whom the company has received due notice as of the record date for entry into the shareholders' register.

Any shareholder who has requested an admission card by **Friday, 27 November 2026, at 11.59 pm CET** at the latest is entitled to attend the general meeting. Shareholders who have issued a proxy or voted by postal vote may also attend the general meeting if they request an admission card within the deadline.

Admission cards for the general meeting may be requested:

- Online through the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com. Requested admission cards will be sent by email to the email address registered in the Shareholder Portal when registering for the general meeting.

  Or

- By sending a completed and signed registration form (attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the registration form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the registration form is sent by ordinary mail.** Admission cards requested using the registration form can be collected at the entrance to the general meeting upon presentation of valid photo ID.

  Or

- By contacting Computershare A/S by telephone +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CET).

Please note that admission cards will not be sent by ordinary mail. Shareholders who have registered for the general meeting in due time, i.e. by **Friday, 27 November 2026 at 11:59 pm CET** at the latest, will be admitted to the general meeting upon presentation of the following at the entrance:

- An electronic admission card on a smartphone/tablet or a printout of the admission card if the shareholder has registered for the general meeting through the Shareholder Portal on the company's website.

  Or

- Valid photo ID if registration was completed by sending the registration form or by telephone.

Shareholders will receive a voting form at the entrance to the general meeting.

Any shareholder who has submitted a proxy to the Chairman of the Board of Directors by using the proxy and postal voting form (attached to the notice) or who has voted by postal vote may attend the general meeting, provided that the shareholder registers for admission in due time.

The shareholder or a proxy holder may attend the general meeting accompanied by an adviser.

For questions concerning registration for the general meeting or use of the Shareholder Portal, please contact Computershare A/S by telephone +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CET).

Voting by proxy

Voting rights may be exercised through a proxy, who must present a written and dated power of attorney appointing the proxy. Such power of attorney cannot be issued for periods exceeding one year.

Proxies must be nominated by **Friday, 27 November 2026 at 11:59 pm CET at the latest** either:

- Via the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com.

  Or

- By sending a completed and signed proxy and postal voting form (attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the proxy and postal voting form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the proxy and postal voting form is sent by ordinary mail.**

Proxies may be revoked at any time.

Postal vote

Shareholders may vote by postal vote on the items on the agenda. Postal votes must be received by Computershare A/S on **Monday, 30 November 2026 at 9:00 am CET at the latest.** Postal votes may be cast either:

- Via the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com.

  Or

- By sending a completed and signed proxy and postal voting form (attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the proxy and postal voting form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the proxy and postal voting form is sent by ordinary mail.**

Postal votes **cannot** be withdrawn.

Processing of personal data

The company processes personal data about its shareholders in compliance with the Danish Companies Act for the purposes of maintaining the company's shareholders' register and sending convening notices and other communication. The following data is processed: names, addresses, contact details, securities account numbers/VP numbers, shareholdings and participation in events. You can read more about how Coloplast processes personal data on our website: https://www.coloplast.com/legal-information/investors-data-privacy/.

Transport

The company will arrange bus transportation from Humlebæk train station to Coloplast and back to the station. Information about departure times is provided together with the attached driving directions.

The Board of Directors

Annex 1

Candidates for the Board of Directors

Jette Nygaard-Andersen (58)
Chairman
Joined the Board in 2015, considered an independent Board member.

Chairman of the Remuneration and Nomination Committee and Member of the Audit Committee.

Other board and management positions:

- LivaNova PLC, (BM) and member of the Nomination and Governance Committee

Jette Nygaard-Andersen has considerable international executive management and board experience within global technology-enabled consumer businesses including global medtech, media and entertainment, leisure, retail and digital growth businesses. Jette brings significant expertise in go-to-market strategies, transformation, optimization of the customer experience and engagement in customer centric businesses, technology & digital competency areas and with M&A. Over the years, Jette has worked within both global large scale companies as well as with digital growth start-ups, helping them scale globally. Jette was most recently CEO of FTSE 50 company Entain plc from 2021-2024 based in London and spend 16 years in CEO roles at MTG AB based primarily in Stockholm and London. Prior to this, Jette worked at Accenture Inc and Maersk A/S.

Niels Peter Louis-Hansen (79)
Deputy Chairman
Joined the Board in 1968, not considered an independent Board member.

Member of the Remuneration and Nomination Committee.

Other board and management positions:

- Aage og Johanne Louis-Hansens Fond, (C)
- Aage og Johanne Louis-Hansen A/S, (C)
- CF Holding af 2026 ApS (C)
- Coloplast Fonden (C)
- Coloplast Holding ApS, (C)
- NPLH Holding ApS, CEO
- N.P. Louis-Hansen ApS, CEO
- NPLH Property Investments ApS, CEO
- NPLH Anpartsinvest ApS, CEO

Through decades of board work, Niels Peter Louis-Hansen has gained in depth knowledge of the industries in which Coloplast operates, its dynamics and key players as well as deep insight into strategy development. Furthermore, Niels Peter Louis-Hansen is a key contributor to preserving the Coloplast culture.

Annette Brüls (55)
Joined the Board in 2021, considered an independent Board member.

Member of the Remuneration and Nomination Committee.

Other board and management positions:

- Edwards Lifesciences, Corporate Vice President, EMEACLA

Annette Brüls has considerable executive management experience within global medical device businesses. In 2024 Annette was appointed Corporate Vice President EMEACLA for Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Before that Annette Brüls was CEO of Medela AG. Annette Brüls has also spent 11 years with Medtronic holding several senior leadership positions in both Europe and the US. Annette Brüls has in depth knowledge and understanding of product development and commercialization within the medtech industry and in particular in chronic disease management, including digital services and value-based healthcare models

Carsten Hellmann (62)
Joined the Board in 2017, considered an independent Board member.

Member of the Audit Committee.

Other board and management positions:

- Chanelle Pharma, (C)
- The Danish Chamber of Commerce, (BM)
- Copenhagen Capacity, The Foundation for the Marketing of Business Promotion, (BM)
- Copenhagen Gaming, Film and Mediafund ApS, (C)
- Den Østdanske Filmfond ApS, (C)

Carsten Hellmann has considerable executive management experience. From 2016 to 2023, Carsten Hellmann was the President & CEO in ALK-Abelló A/S.
Carsten Hellmann has extensive experience in product development and international commercialization within highly regulated industries as well as M&A activities, including post integration.

(C) Chairman – (BM) Board Member

Candidates for the Board of Directors

Marianne Wiinholt (61)
Joined the Board in 2020, considered an independent Board member.

Chairman of the Audit Committee.

Other board and management positions:

- KONGSBERG Gruppen ASA, (BM)
- Norsk Hydro ASA, (BM) and chairman of the audit committee

Marianne Wiinholt has considerable executive management experience. From 2022-2026 Marianne Wiinholt acted as CFO in WS Audiology A/S which was formed in 2019 through the merger of Sivantos and Widex. Previously, Marianne Wiinholt acted as CFO in Ørsted A/S. Marianne Wiinholt has extensive experience within finance and accounting and considerable knowledge and experience in leading, driving and delivering a sustainability agenda on a global scale.

Niels B. Christiansen (60)
Joined the Board in 2025, considered an independent Board member.

Member of the Remuneration and Nomination Committee.

Other board and management positions:

- Lego A/S, CEO & President
- Lego Holding A/S, CEO
- Tetra Laval Group, (BM)

Niels B. Christiansen has considerable executive management and board experience. Niels B. Christiansen is currently CEO and President of LEGO A/S, a role Niels has held since 2017. Prior to this Niels B. Christiansen was the CEO of Danfoss from 2008 to 2017 and was Chairman of the Board of Directors of Demant A/S from 2017-2026. Niels B. Christiansen has extensive leadership experience in major, global, high-tech, consumer goods and industrial enterprises as well as significant insight into industrial policy and sustainability/ESG.

Charl van Zyl (59)
New Board member, considered an independent Board member.

Other board and management positions:

- H. Lundbeck A/S, President & CEO
- Bavarian Nordic A/S, (BM) and member of the Nomination and Compensation Committee and the Science and Technology Committee

Charl van Zyl has considerable executive management experience from international commercial leadership roles within the pharmaceutical industry. Charl van Zyl has been President & CEO of H. Lundbeck A/S since 2023. Prior to this, Charl van Zyl was Executive Vice President and Head of Neurology at UCB Biopharma, where Charl van Zyl also served as Chief Operating Officer. Charl van Zyl has extensive leadership experience within global, highly regulated healthcare businesses as well as significant insight into commercialization, product development and innovation.

(C) Chairman – (BM) Board Member

Bus transportation

In connection with the general meeting on Tuesday, 1 December 2026, there will be busses driving approximately every 10 minutes from Humlebæk train station (country side) to Coloplast and return at the following times:


From Humlebæk Station to Coloplast:	**From Coloplast to Humlebæk Station:**
2 pm until 3:30 pm	At the end of the general meeting approximately at 4:30 pm until 5:30 pm

The bus is parked in the square west of the railway at Humlebæk station (at Humlebæk Center).

Driving directions

By car from Copenhagen drive the E47 to Helsingør. Leave the motorway at exit 5 and turn right. At the first intersection turn right at Hørsholmvej.

The general meeting will be held in the auditorium at Holtedam 3, this is the second road on the right after the intersection.



The Coloplast story begins back in 1954. Elise Sørensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister's problems, Elise conceives the idea of the world's first adhesive ostomy bag.

Based on Elise's idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis-Hansen, a trained nurse, created the ostomy bag. A bag that does not leak, giving Thora – and thousands of people like her – the chance to live the life they want.

A simple solution that makes a difference.

Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2026-11.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Coloplast

Coloplast A/S
Holtedam 1
3050 Humlebaek
Denmark

Company registration (CVR) No. 69 74 99 17